戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 k wave alone in improving ischemia in rodent critical limb ischemia.
2 therapeutic target in diabetic patients with critical limb ischemia.
3 therapeutic utility in elderly patients with critical limb ischemia.
4  amputations in patients with below-the-knee critical limb ischemia.
5  bleeding in patients undergoing surgery for critical limb ischemia.
6 e form of HIF-1alpha, in a diabetic model of critical limb ischemia.
7  treatment for peripheral artery disease and critical limb ischemia.
8 omes among specific treatment modalities for critical limb ischemia.
9 a-initiated blood flow recovery resulting in critical limb ischemia.
10  an increased odds of death in patients with critical limb ischemia.
11 sions, is an effective primary treatment for critical limb ischemia.
12 eutic angiogenesis in selected patients with critical limb ischemia.
13 ential therapeutic benefits in patients with critical limb ischemia.
14 -the-knee arterial disease in patients with -critical limb ischemia.
15 myocardial infarction but not prior acute or critical limb ischemia.
16 likelihood of limb preservation in mice with critical limb ischemia.
17 r surgical bypass in patients diagnosed with critical limb ischemia.
18 to modify the natural history of intractable critical limb ischemia.
19  for intractable peripheral arterial disease/critical limb ischemia.
20  the patients had claudication, and 4.6% had critical limb ischemia.
21 pathophysiology, diagnosis, and treatment of critical limb ischemia.
22 e treatment of peripheral artery disease and critical limb ischemia.
23 s are positively correlated in patients with critical limb ischemia.
24 ise performance and the potential to develop critical limb ischemia.
25 a key role in the treatment of patients with critical limb ischemia.
26 he most severe manifestation of the disease, critical limb ischemia.
27  to reduce amputation rates among those with critical limb ischemia.
28 ion is upregulated in patients and mice with critical limb ischemia.
29 n patients with symptomatic claudication and critical limb ischemia.
30 pond to medical management and patients with critical limb ischemia.
31 n were older and have multilevel disease and critical limb ischemia.
32 te limb ischemia or an acute exacerbation of critical limb ischemia.
33 from T2DM patients undergoing amputation for critical limb ischemia.
34 w-the-knee lesions in diabetic patients with critical limb ischemia.
35 ese acute presentations were attributable to critical limb ischemia.
36 rarefaction, especially when associated with critical limb ischemia.
37 /-2.4% and 8.3+/-3.1%, log-rank P<0.001) and critical limb ischemia (19.1+/-4.8% and 31.6+/-6.3% at 1
38 ompared with acute limb ischemia (75.3%) and critical limb ischemia (92.6%; P<0.001).
39                                              Critical limb ischemia, a manifestation of severe periph
40 a on the incidence and long-term outcomes of critical limb ischemia, acute limb ischemia, or acute vi
41 dence interval, 1.69-5.35), particularly for critical limb ischemia (adjusted risk ratio, 5.96; 95% c
42 ons, poor distal runoff, and the presence of critical limb ischemia all have contributed to the disap
43 orary patterns in management and outcomes of critical limb ischemia among United States veterans are
44                                 In contrast, critical limb ischemia and acute limb ischemia threaten
45 dred twenty-five limbs (of 89 patients) with critical limb ischemia and ankle brachial index >/=1.4 w
46 e policies that will reduce the incidence of critical limb ischemia and enhance delivery of optimal c
47 lation of S100A1 expression in patients with critical limb ischemia and identifies S100A1 as critical
48 transplanted in patients with myocardial and critical limb ischemia and in animal models.
49     Conclusions and Relevance: Understanding critical limb ischemia and its treatment strategies is i
50                          Among patients with critical limb ischemia and noncompressible ankle brachia
51 s with end-stage vascular disease, including critical limb ischemia and refractory myocardial ischemi
52 main clinical presentations of claudication, critical limb ischemia, and acute limb ischemia.
53 chial index, quality of life, progression to critical limb ischemia, and revascularization procedures
54 n graft operations performed exclusively for critical limb ischemia at 83 North American centers.
55 ersus Best Surgical Therapy in Patients With Critical Limb Ischemia (BEST-CLI) study is a randomized
56 ation data to identify patients admitted for critical limb ischemia between 2005 and 2014.
57                             In patients with critical limb ischemia caused by infrapopliteal lesions,
58  intermittent claudication (IC) (n = 23) and critical limb ischemia (CLI) (n = 23).
59 pies, a significant portion of patients with critical limb ischemia (CLI) are considered as "no optio
60                                              Critical limb ischemia (CLI) continues to be a major cau
61 ded a substantial cohort of patients without critical limb ischemia (CLI) have not been described.
62 ients (claudication 101 patients (36.7%) and critical limb ischemia (CLI) in 174 patients (63.3%).
63 obust and clinically relevant swine model of critical limb ischemia (CLI) involving the onset of isch
64                                              Critical limb ischemia (CLI) is a clinical syndrome of i
65                                              Critical limb ischemia (CLI) is a life- and limb-threate
66 ex differences in management and outcomes of critical limb ischemia (CLI) is conflicting.
67                                              Critical limb ischemia (CLI) is the most advanced stage
68                                              Critical Limb Ischemia (CLI) is the most advanced stage
69                                              Critical limb ischemia (CLI) leads to a high rate of lim
70                                              Critical limb ischemia (CLI) morbidity and mortality rat
71  impact of severe cardiovascular disease and critical limb ischemia (CLI) on the bone marrow (BM) is
72 raight inline arterial flow in patients with critical limb ischemia (CLI) or lifestyle-limiting claud
73  of tibioperoneal vessel angioplasty (TPVA), critical limb ischemia (CLI) patients' data were analyze
74  constitute a major health care burden among critical limb ischemia (CLI) patients.
75 ents (MACCE) and amputation-free survival in critical limb ischemia (CLI) patients.
76 : (1) to profile miR expression in PACs from critical limb ischemia (CLI) patients; (2) to demonstrat
77 ural vascular care obtained by patients with critical limb ischemia (CLI) remains unknown.
78  used tobacco, 78 665 of 168 553 (45.7%) had critical limb ischemia (CLI), and 13 296 of 168 553 (7.9
79 ients are hospitalized for the management of critical limb ischemia (CLI), but limited data are avail
80                                              Critical limb ischemia (CLI), foot ulcers, former amputa
81                                              Critical limb ischemia (CLI), the most advanced form of
82 laudication, that is, pain with walking, and critical limb ischemia (CLI), which includes pain at res
83 us oxygen tension (TcPo(2)) in patients with critical limb ischemia (CLI).
84  severe form of peripheral artery disease is critical limb ischemia (CLI).
85 herapeutics for cardiovascular diseases like critical limb ischemia (CLI).
86 ence of peripheral arterial disease (PAD) or critical limb ischemia (CLI).
87 cal revascularization (SR) for patients with critical limb ischemia (CLI).
88 ting with intermittent claudication (IC) and critical limb ischemia (CLI).
89 m cells (MSC) are promising therapeutics for critical limb ischemia (CLI).
90 oss of injected stem cells in PIRI including critical limb ischemia (CLI).
91 ascularization improvements in patients with critical limb ischemia (CLI).
92  arterial revascularization in patients with critical limb ischemia (CLI).
93 g from peripheral arterial diseases, such as critical limb ischemia (CLI).
94  been successfully used for the treatment of critical limb ischemia (CLI).
95 y showed scarcity of BM PCs in T2DM and T2DM+critical limb ischemia compared with C, but similar leve
96  we identified incident cases with a primary critical limb ischemia diagnosis who received PTA, stent
97 mb events (new-onset claudication, new-onset critical limb ischemia, EVT, and nontraumatic amputation
98                          Black patients with critical limb ischemia face significantly higher risk of
99                                Patients with critical limb ischemia had the highest TAC scores, and i
100                                Patients with critical limb ischemia have a perioperative cardiovascul
101                                Patients with critical limb ischemia have multiple comorbidities, and
102  undergoing ankle brachial index testing for critical limb ischemia have noncompressible vessels beca
103                           Most patients with critical limb ischemia have severe below-the-knee arteri
104 d to Improve Limb Perfusion in Patients With Critical Limb Ischemia (HGF-STAT trial) determined the e
105 acement, atherectomy, or surgical bypass for critical limb ischemia, high mortality and major amputat
106   Bone marrow cell (BMC)-based treatment for critical limb ischemia in diabetic patients yielded a mo
107 ll (EC)-mediated angiogenesis contributes to critical limb ischemia in diabetic patients.
108 novel avenues for cell-based therapeutics of critical limb ischemia in diabetic patients.
109 ells might exert enhanced protection against critical limb ischemia in rats.
110 enitor cell-extracorporeal shock wave) after critical limb ischemia induction.
111                                   RATIONALE: Critical limb ischemia is a life-threatening complicatio
112                                              Critical limb ischemia is a manifestation of peripheral
113                                              Critical limb ischemia is characterized by rest pain and
114  is most commonly caused by atherosclerosis, critical limb ischemia is heavily associated with smokin
115 use completely, amputation will not occur if critical limb ischemia is not already present.
116  Best Open Surgical Therapy in Patients with Critical Limb Ischemia) is attempting to answer whether
117 les were reviewed if they included the terms critical limb ischemia, ischemic rest pain, gangrene, or
118 apacity and are at risk of acute and chronic critical limb ischemia leading to major adverse limb eve
119      In a prespecified analysis, PAD events (critical limb ischemia, limb revascularization, or amput
120                          Importance: Chronic critical limb ischemia, marked by intractable lower extr
121 ity amputation, peripheral vascular disease, critical limb ischemia, osteomyelitis, and ulcer.
122                                              Critical limb ischemia patients have a 1-year amputation
123 c donors, and on blood vessels from diabetic critical limb ischemia patients undergoing a lower-limb
124 rdiovascular risk and prevent progression to critical limb ischemia, patients with PAD continue to be
125                             In patients with critical limb ischemia, perioperative dual antiplatelet
126                                              Critical limb ischemia portends a risk of major amputati
127 rdiovascular events, and patients with prior critical limb ischemia, prior lower extremity revascular
128  vascular team approach for the treatment of critical limb ischemia, pulmonary embolism, acute ischem
129 e findings persisted after stratification by critical limb ischemia, race, dual enrollment, and regio
130 ersus Best Surgical Therapy in Patients With Critical Limb Ischemia) randomized controlled trial comp
131         In total, 34 no-option patients with critical limb ischemia received HIF-1alpha at doses of 1
132 sis >50%, retreatment, major amputation, and critical limb ischemia-related death were regarded as tr
133                                              Critical limb ischemia remains a difficult disease to tr
134                                    Findings: Critical limb ischemia represents the end stage of perip
135                     In its most severe form, critical limb ischemia, rest pain, and tissue necrosis a
136 ilure of vein bypass grafts in patients with critical limb ischemia results in morbidity, limb loss,
137                                  Adults with critical limb ischemia (Rutherford category >/=4) and in
138   Inclusion criteria were diabetes mellitus, critical limb ischemia (Rutherford class 4 or higher), s
139 and limb salvage in patients presenting with critical limb ischemia; secondary aims include (1) cost-
140                        Patients with chronic critical limb ischemia showed almost complete loss of S1
141                                 Twenty-eight critical limb ischemia subjects were randomized and trea
142              Conclusion In participants with critical limb ischemia, the drug-coated balloon angiopla
143                            For patients with critical limb ischemia, the goals of revascularization a
144                                              Critical limb ischemia, the most severe form of peripher
145 dures because of acute coronary syndromes or critical limb ischemia, the outcomes are less favorable
146  below-the-knee lesions in participants with critical limb ischemia through 12 months.
147 findings link its pathological plasticity in critical limb ischemia to impaired neovascularization, p
148 ivided into group 1 (sham control), group 2 (critical limb ischemia treated with culture medium), gro
149 progenitor cells [2.0 x 10 cells]), group 4 (critical limb ischemia treated with extracorporeal shock
150 hemia treated with culture medium), group 3 (critical limb ischemia treated with intramuscular bone m
151 tion of restenosis in diabetic patients with critical limb ischemia undergoing endovascular intervent
152 ing with either intermittent claudication or critical limb ischemia undergoing FP intervention were r
153 ar infrapopliteal treatment of patients with critical limb ischemia using percutaneous transluminal a
154          HIF-1alpha therapy in patients with critical limb ischemia was well tolerated, supporting fu
155              Here, in a preclinical model of critical limb ischemia, we assessed a novel method of ce
156              A total of 20 938 veterans with critical limb ischemia were hospitalized between 2005 an
157 inguinal revascularization or amputation for critical limb ischemia were maintained on aspirin (75 mg
158                                 Diabetes and critical limb ischemia were present in >50% in both grou
159 ascularization increased among veterans with critical limb ischemia, which was accompanied by a reduc
160 cells in subjects with moderate or high-risk critical limb ischemia, who were poor or noncandidates f
161                      Treating below-the-knee critical limb ischemia with DES is an effective and safe
162                   Tissues from patients with critical limb ischemia with EndMT features exhibited sig
163 e-blind superiority study, participants with critical limb ischemia with rest pain or tissue loss wit
164 a) into the lower extremity of patients with critical limb ischemia would be safe and might result in

 
Page Top